Centogene N.V., a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, closed a EUR 15 million (approx. USD 17 million) private placement financing from investors led by DPE Deutsche Private Equity, TVM Capital Life Science, and Careventures (the “Private Placement Financing”), as well as the entry into a USD 45 million senior secured loan facility provided by Oxford Finance.

“CENTOGENE has built a strong position in the field of rare, metabolic, and neurodegenerative diseases by providing precise medical diagnosis at the earliest possible moment,” said Christopher A. Herr, Senior Managing Director at Oxford Finance. “Through this partnership, the Company is positioned to continue generating leading edge medical insights and broaden its set of biopharma and pharmaceutical partners globally.”

The Private Placement Financing includes the sale of 4,479,088 shares of common stock at a price per share of USD 3.73 and warrants to acquire up to 1,343,727 additional shares of common stock at an exercise price per share of USD 7.72. Under the terms of the Loan Facility, CENTOGENE has drawn down USD 25 million and will have access to a second tranche of USD 20 million upon the achievement of certain conditions.

Moelis & Company served as CENTOGENE’s financial advisor in connection with the financings.